Every year, more than 3,000 scientific abstracts are accepted for oral and poster presentation at the Society's annual meeting.
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to biomedical research
The American Society of Hematology (ASH) leads the world in promoting and supporting clinical and scientific hematology research through its many innovative award programs, meetings, publications, and advocacy efforts.
Blood is the official journal of the American Society of Hematology and the most cited peer-reviewed publication in the field. It is published weekly every Thursday, except for the last week in December, in addition to the ASH Annual Meeting Abstracts issue in November.
Explore programs offered by ASH to support clinical and scientific hematology research
ASH's strategic plan highlighting the importance of placing hematology as a top funding priority in the healthcare community
Although the Transfusion Requirements in Critical Care (TRICC) trial showed the benefits of a conservative transfusion strategy more than 15 years ago, many physicians remain skeptical about the safety of lower hemoglobin thresholds for red cell transfusion in critically ill patients.
While it is commonly understood that the environment and heredity contribute to the development of cancer, what if something else contributed to carcinogenesis?
Animal studies suggest that inhibition of factor XI (FXI) prevents thrombosis without disrupting hemostasis. Epidemiologic data indicate that patients with congenital FXI deficiency are protected from venous thromboembolism (VTE), even though their bleeding phenotype is variable and often quite mild.
T-cell acute lymphoblastic leukemia (T-ALL) represents 10 to 15 percent of newly diagnosed cases of acute leukemia and is notable for its distinctive biological features and aggressive clinical course. While outcomes were once inferior, they now approach those observed in B-lymphoblastic disease (B-ALL).
On February 6, 2014 the leadership of the House Ways and Means and Energy and Commerce Committees and the Senate Finance Committee released a bi-partisan and bicameral bill to repeal the Sustainable Growth Rate (SGR) formula that has driven annual reductions in Medicare payment for physician services.
On Thursday, December 26, President Obama signed the Bipartisan Budget Act of 2013 (BBA). This agreement included the Pathway for SGR Reform Act of 2013, a provision of the budget framework which prevents the scheduled Medicare payment reduction from taking effect on January 1, 2014 and provides for a 0.5 percent increase for Medicare payments for services performed from January 1, 2014 through March 31, 2014.
On December 12, 2013 the House Ways and Means Committee and the Senate Finance Committee passed similar bills to repeal the Sustainable Growth Rate (SGR) formula that drives annual reductions in Medicare payment for physician services.
President Obama has announced the nomination of Vivek Hallegere Murthy, MD, MBA, to be the next U.S. Surgeon General.
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to biomedical research.
September 17-19, 2015 Fairmont Chicago, Millennium ParkChicago, IL
ASH, the leading authority on malignant hematology, presents its newest clinical meeting.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology